LeMaitre Vascular, Inc. (LMAT) to Issue Quarterly Dividend of $0.20 on December 4th

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Monday, October 27th. Investors of record on Thursday, November 20th will be given a dividend of 0.20 per share by the medical instruments supplier on Thursday, December 4th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Thursday, November 20th.

LeMaitre Vascular has raised its dividend by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a dividend payout ratio of 33.6% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 36.9%.

LeMaitre Vascular Stock Down 1.4%

LMAT stock opened at $87.20 on Tuesday. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $1.98 billion, a P/E ratio of 42.23, a PEG ratio of 2.29 and a beta of 0.77. LeMaitre Vascular has a twelve month low of $71.42 and a twelve month high of $109.58. The firm has a 50 day simple moving average of $88.71 and a 200-day simple moving average of $86.89.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The firm had revenue of $61.05 million during the quarter, compared to the consensus estimate of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS. Q4 2025 guidance at 0.640-0.690 EPS. On average, equities research analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of research reports. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. Barrington Research reiterated an “outperform” rating and issued a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Cantor Fitzgerald restated a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Finally, Roth Capital reiterated a “buy” rating and issued a $108.00 target price on shares of LeMaitre Vascular in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.20.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.